RHAMM is hyaluronan-receptor with multiple functions in the cell, RHAMM is involved in proliferation, motility, migration, invasion, mitotic spindle formation in tumour cells. Therefore, RHAMM could be a relevant target for molecular targeted therapies against tumors.The role of RHAMM-target peptides in inhibition invasion for preventing breast cancer has not yet been investigated. Base on this, we analyzed the RHAMM-target peptides for their therapeutic activity against breast cancer cells. In the present study, we examined the effect of RHAMM-target peptides on the invasion of breast cancer cells (MDA-MB-231), using confocal microscopy. We shown that RHAMM-target peptides decreased formation of invadopodia of breast cancer cells. The treatment of breast cancer cells by RHAMM -target peptides inhibited the invasion up to 99 %. Additionally, RHAMM-target peptides induced the morphological changes of of breast cancer cells. Therefore, based on these results, we can conclude that RHAMM-target peptides may be potential anti-cancer agents.
Introduction
Cancer is on the second place after the disease of the cardiovascular system. Every year, 10 million new cases of malignant tumors and more than 5.2 million cancer related deaths are recorded (1) . Despite the increase in diagnostic capabilities the proportion of active cases and the proportion of patients with the disease have been identified at an early stage of tumor, remains low (2) . Thus, high mortality rates, poor diagnosis of malignant tumors, show the need for the development of new diagnostic and therapeutic methods, and events for medical and diagnostic care to cancer patients. The major scientific problem is the development of new targeted approaches for the diagnosis and treatment of cancer. Lack of specificity of anticancer drugs, remains a major challenge oncology (3) .
The fundamental goal of cancer research is identification of therapies that induce selective cancer cell death. Therapeutic peptides are increasingly gaining popularity for medical use in a variety of applications, including tumour vaccines, antimicrobial therapy and nucleic acid delivery (4, 5) . Guidelines for using the peptides to treat cancer include the following approaches: the direct use of peptides as drugs (angiogenesis inhibitors), targeted agents, carriers of cytotoxic drugs and radionuclides (targeted therapy and radiation therapy), hormones and vaccines; the use of peptides as biomarkers of cancer and regulators and progression of cancer, since peptides are capable of specifically binding to the various receptors, as well as part of the signal transduction pathways (6) (7) (8) . The direct use of peptides as therapeutic agents for the treatment of cancer is gaining momentum in recent years. The antitumor activity of different peptides based on the mechanisms of action, limiting growth tumour (9) . These mechanisms include inhibition of angiogenesis, inhibition of protein-protein interactions, inhibition of enzymes, proteins, blocking the signal transduction pathways or gene expression (10, 11) . Another category of anti-peptides act as a peptide antagonists which preferentially bind to a known receptor. It was shown, that RHAMM-binding peptides specifically bind to RHAMM receptor, block the signal pathway, induce the apoptosis, necrosis of cancer cells (12, 13) . Such selective peptides have great prospects, because their main mechanism of action targeted to a specific molecular target cancer cells that may lead to cell death (14, 15) . Another type of peptides is capable to destroy the cell membrane of cancer cells. For example, it is known that membrane-lytic peptides such as cationic antimicrobial peptides able to physically destroy the cytoplasmic and mitochondrial membranes of cancer cells, leading to their death (16) (17) (18) (19) . Many natural or synthetic "pro-apoptotic" peptides act as therapeutic agents able to induce apoptosis, induce cell death or enhance the effect of chemotherapy drugs. For example, so-called cell-penetrating peptides have been used in the treatment of cancers because they greatly increased efficiency anti-cancer drugs commonly used in chemotherapy (20) (21) (22) (23) . It is shown that necrotic peptides isolated Australian frogs and toads, or from the stings of insects, as well as various protective peptides derived from various organisms, also have a moderate anti-tumor activity (24) (25) (26) (27) . Another example is depsipeptides which show a wide range of biological activity. These depsipeptides possess antitumor activity selectively cytotoxic to cancer cells, reduce multi-drug resistance of tumours (28) (29) (30) (31) (32) (33) . The literature on using peptides, especially for cancer targeting is steadily increasing (34) .
Thus, targeted chemotherapy and targeted delivery of drugs based peptides are excellent tools to minimize the problems of traditional chemotherapy. At present time the different approaches exist, including the addition a targeting ligand, increasing the binding affinity or activation of the penetration at the correct site (35) (36) (37) . However, use of peptides in vivo is limited by their low stability, cell permeability and absence of high selectivity to target.
RHAMM/HMRR is a multifunctional extracellular and intracellular protein, a receptor of hyaluronan mediated motility, which use hyaluronan (HA) as a substrate and bind to microtubules, participating in control of mitotic-spindle integrity (38) . HA is a polysaccharide that involved in structural and signaling functions of cells, which are important for immunity, tissue organization and homeostasis (39, 40) . The function of HA depends from its size, large HA fragments are responsible for structural functions, while the small HA fragments bind and interact with cell receptors such as CD44 and RHAMM. These small HA fragments induce signaling pathways that control proliferation, differentiation, cell-adhesion, motility and invasion cells (41) (42) (43) (44) . High expression of HA is associated with onset of such diseases as arthritis, diabetes and cancer (45) (46) (47) . It is known now, that inside of cell, RHAMM is responsible for proliferation, motility, invasion of tumour cells (44, (48) (49) (50) (51) (52) .
It was demonstrated that RHAMM-expression dramatically increased in many different types of cancer cells, such as myeloid leukemia, colorectal, breast, prostate, ovarian, multiple myeloma, gastric cells. It shown that such overexpression of RHAMM and HA correlates with poor prognostic factor (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) (65) (66) (67) (68) (69) . In experimental tumour models, RHAMM is an oncogenic protein that promotes both signalling through the RAS-ERK1,2 pathway and mitotic spindle instability leading to aberrant chromosome segregation (61, 62) . Carboxyl terminal RHAMM sequence, which contains the HA and microtubule binding regions, is required for its oncogenic effects in these cancer models (61) . Therefore, RHAMM could be a relevant target for molecular targeted therapies against tumors. The RHAMM-target peptides were design and characterized, and it was showed, that they were the most specific and selective ligands for RHAMM, they were stable in serum and they easily penetrate to cells (63) . These peptides also demonstrated the selective cellular uptake by breast and prostate cancer cells MDA-MB-231, they inhibited proliferation and induced apoptosis in prostate cancer cells (63) . Based on this, we analyzed the therapeutic potential of RHAMM-target peptides for treatment breast cancer.
The goal of this research is investigation of the effect RHAMM-target peptides on invasion breast cancer cells.
Materials and Methods
Abbreviations: Fetal bovine albumin (FBS), phenyl-nitroanilide (pNA), Dulbecco's modified Eagle's medium (DMEM), Enzyme-linked immunosorbent assay (ELISA), EEDFGEE-AEEEA (p.#35), VEGEGEEGEEY (p.#37), FTEAESNMNDLV (p.#40), 3,3′,5,5′-tetramethylbenzidine (TMB)
Materials
DMEM and FBS were purchased from Multicell (Canada), HEPES was purchased from Sigma (USA), trypsin was purchased from Gibco BRL (USA), Triton X-100 was purchased from Bioshop (Canada), plastic tissue culture dishes were purchased from BD Falcon (USA), QCM TM Gelatin Invadopodia assay (red) kit was purchased from Millipore (USA), Quick Start Bradford Protein Assay (Bio-RAD, USA).
Cell lines and cell culture
Human breast carcinoma cell lines (MDA-MB-231, MCF-7), 10T ½ cells and RHAMM ( -/-) Mefs cells were obtained from American Type Culture Collection (Manassas, VA) and were cultured in DMEM supplemented with 10 % (v/v) heat-inactivated FBS and 10 mM HEPES at pH 7.2. All cultures were incubated in a humidified atmosphere of 5 % CO 2 at 37 0 C.
Protein detection
Protein has been measured by Quick start Bradford protein assay using standard procedure.
Fluorescent gelatin degradation assay for investigation of invadopodia formation
To study effect of RHAMM-target peptides on invadopodia formation, the QCM TM Gelatin Invadopodia assay (red) kit was used. All procedures carried out according to the manual protocol. Mefs cells were cultured to 70-80 % confluence in tissue culture plates. Cells were detached using 0.25 % trypsin-EDTA, then pelleted, followed re-suspension in growth medium to a concentration of 1, 000 cells/ml. Cells were seeded in a volume of 500 µl/well and cultured for the desired duration of degradation for 24 hrs.
Cell lines used

Preparation of substrate and seeding of cells
Briefly, 24-wells glass chamber slides were first coated with 250 µl/well of dilute poly-L-lysine. Then the poly-L-lysine was removed. Next, 250 µl of dilute glutaraldehyde in DPBS was added to each well for activation of the poly-L-lysine surface. Then each well was again washed three times with 500 µl of DPBS. Finally, 200 µl of gelatin mixed at a 1:5 ratio of fluorescently-labeled: unlabeled gelatin, was coated onto each well for 10 min. All steps were performed in the dark to protect the glass slides from photobleaching. The gelatin substrates were disinfected, using 500 µl/well of 70 % ethanol for 30 min at RT. After this step, free aldehydes were quenched by the addition of 500 µl/well of amino-acid-containing growth medium. Cell types of interest were detached and seeded as described in the previous section and incubated at 37 0 C in 5 % CO 2 for 24 hrs. For the experiments, involving a modulation of invadopodia formation, the RHAMM-target peptides (40 µg/ml final concentration) in DMEM were added and incubated at 37 0 C in 5 % CO 2 for 40 hrs.
Sample fixation and staining
After 40 hrs incubation with RHAMM-target peptides, the samples were fixed for 30 min at RT with 250 µl/well of 3.7 % formaldehyde in DPBS. Samples were then washed three times with 500 µl/well of fluorescent staining buffer. After this step, samples were incubated during 1 hr at RT with FITC-conjugated phalloidin (2 µg/ml) and DAPI (1µg/ml) in staining buffer. After staining, the cells were mounted on a glass slide and immediately analyzed under a laser confocal microscope, using excitation wave at 358, 494 and 550 nm. We performed all experiments were in triplicate and repeated three times.
Confocal microscopy
Confocal images were captured, using a laser-scanning confocal microscope (Fluoview FV-1000; Olympus) at x20 objective magnification for quantification studies (5 fields of view per well) with a 1.0 zoom factor or 60X PlanApo/1.45 objective magnification (oil immersion) with a 2.0 zoom factor and then images were analyzed with Fluoview software (FV10-ASW version 01.07: Olympus).
Image analysis "Percent degradation area of total cell area" was quantified using ImageJ analysis software, kindly distributed by the National Institute of Health (NIH). A high intensity threshold was used for positive DAPI signal, then analyzed as "particles" for determination of a nuclear (cells) count. Similarly, setting a high intensity threshold for FITC-phalloidin signal enabled measurement of total cell area per field of view. Conversely, a low intensity threshold was set for diminished fluorescent gelatin signal to enable quantification of total degradation area per field of view.
Statistical analysis
Prism 4 software (GraphPad Software, Inc.) was used to perform tests for statistical significance. For statistical comparison, one-way analysis of variance (ANOVA) was used with P<0.05 considered significant. 
Results
RHAMM-target Peptides Inhibited the Invasion of MDA-MB-231 Cells.
Over 100 cells per condition were analyzed to obtain the "percent degradation area of total cell area" data depicted in Figures 1. It should be point out, that although the theoretical maximum of "percent degradation area of total cell area" consists 100 %, we observed here the higher amounts of degradation, because of cellular movement during proteolysis. Because of higher level of degradation gelatin matrix was observed after culture cells for 40 hrs, in our next experiments we used this time to examine effect RHAMM-target peptides on invasion cancer cells.
To analyze whether RHAMM-target peptides can inhibit the invasion of breast cancer cells, we seeded MDA-MB-231 cells onto fluorescein-gelatin matrices and then treated with RHAMM-target peptides or a DMEM control for 40 hrs. Then we visualized and quantified the degradation of fluorescein gelatin matrix by MDA-MB-231 cells. It was shown, that untreated MDA-MB-231cells (DMEM control) demonstrated gelatin proteolysis and degradation patterns, which are attributed to invadopodia or podosome formation. These areas devoid of fluorescein-gelatin fluorescence (Fig. 1) . Our results shown that MDA-MB-231 cells (DMEM control) degraded about 70 % of total cell area, whereas no degradation by (non-forming cancer) 10 T1/2 cell types (Fig. 2) or non-invasive RHAMM ( -/-) cells was observed (Fig. 3) . RHAMM-target peptides inhibited the invasion MDA-MB-231 cells during the 40 hrs treatment (Fig. 4 row A, (Fig. 4 row B) degraded the 33 % of total cell area, so the inhibition of invasion was 67 %. The cells-treated with peptide #40 demonstrated the highest-level inhibition of invasion almost on 100 % (Fig. 4 row C) .
Quantification analysis of degradation area normalized to number of MDA-MB-231 cells also indicated that all three peptides decreased significantly the degradation area of MDA-MB-231 cells (Fig. 5 ). These data demonstrate that RHAMM-target peptides inhibit the invadopodia formation and invasion of MDA-MB-231 cells.
Treatment with RHAMM-target peptides changes the morphology breast cancer cells during invasion process
We analyzed the population of cells in invasion assay, using images with high magnification x60. Using invasion assay, we find out, that after treatment cells with peptides there are strong morphological (and, probably, biochemical) differences inside population MDA-MB-231 cells during the process invasion. We noticed the appearance senescent cells in population, that perfectly correlates with the start invasion process (Fig.  4A, B, C) . These data indicate, that these senescent cells somehow involved in invasion process. These cells had a different morphology, big-size (their size is in approximately > 10 times bigger compared to regular cells), big nucleus, round shape morphology, absence invadopodia (Fig. 6C) . Additionally, the senescent cells contain many nucleus inside, their amount varies from 2-, 4-up to 6 nuclei per cell. The function of these senescent cells is not known yet. However, we noticed, that they interact, associate with of cancer cells, regular size (Fig. 4A , B, C; 6C), they were always surrounded by these cells, which were invasive and co-localized with area degradation of matrix. These regular cancer cells have typical malignant cell morphology, elliptical shape, long-size of invadopodia, polarized cell morphology (Fig. 6A, B) .
The actin was localized at the edges of cells and extensively accumulated at the ends of invadopodia, which allows them to degrade matrix and invade inside. The actin was organized, no aberrant stress fibers, shape of cells perfectly correlated with area degradation (Fig. 6B) . Cell-treated with RHAMM-target peptides showed the senescent and regular cancer cells in population (Fig. 7, 8) . The senescent cells demonstrated uncharacteristically round morphology, showed aberrant actin stress fibers in cytoplasm, actin was not accumulated at the edges of cells, the cells did not have any invadopodia (Fig. 7) .
Additionally, the invasive cells (treated with RHAMM-target peptides showed smaller amount of invadopodia, more short size invadopodia, more round shape and they did not accumulate of actin at the invadopodia edge (Figure 8 ). 
Discussion
Surgery and chemotherapy are usually used for treatment cancer. However, in many cases the anti-cancer drugs are very toxic to the whole organism and destroy the healthy cells of body (70) , and produce side effects. Therefore, we need a development the novel anticancer drugs with higher specificity, low toxicity, selective targeting cancer cells and without side effects. RHAMM is ideal molecular target for anti-cancer therapeutic agents, because it is hyper expressed in tumour tissues, such as breast cancer (60, 61, 71) , leukemia (72) , colon cancer (73) , oral squamous cell carcinoma (74) , aggressive fibromatosis (75), endometrial carcinoma (76, 77) as well as multiple myeloma (58) .
Previously, we demonstrated that RHAMM-target peptides interact with HA binding domain of RHAMM with high selectivity and specificity (12, 13) . These RHAMM-target peptides have a small size (M.w. 4 kDa), analogous distribution of negative charges, such as seen in HA, and they interact with cell surface RHAMM and easily penetrate inside of cancer cells. We demonstrated that these peptides were stable in serum and they blocked RHAMM/HA interactions in various in vitro as-says. Probably, these peptides also bind to MAPs and motor proteins, because their molecules possessing similar degree of negative charges, such as seen in HA. In our previous study, we showed that these peptides induced apoptosis and inhibited cell viability of prostate cancer cells (11, 14) . These results indicated that these peptides may be used as therapeutic agents for treatment cancers in which RHAMM and HA hyper-expression or accumulation is linked to poor outcome (43, 44, (57) (58) (59) (60) .
The invasion of cells is very important for movement, motility and migration of cells. The invasion of cancer cells is crucial step in tumor metastasis. The process of invasion is very complex event and includes many steps, such as adhesion cell to the matrix, activation of proteases enzymes, degradation of proteins of extra-cellular matrix, formation of invadopodia, accumulation actin at the edges of filaments, and movement of the cell body through the hole in the extra-cellular matrix (78) . Many different proteins participate in each of these steps, such as actin, tubulin, integrins, proteases, kinases and cytoskeleton proteins. But the most important feature of invasion process is the formation of invadopodia or podosomes, which have a high proteolytic activity. Additionally, many other molecules involved in the formation and function of invadopodia. It was shown that many events are involved in this process, such as Src phosphorylation of scaffolding protein Tks5 (79) , N-WASP activation, cortactin regulation of the Arp2/3 complex, actin polymerization (80, 81) , generation of reactive oxygen species by NADH oxidases (82), overexpression of matrix metalloproteinases (83) .
Here we demonstrated the proteolytic time-course degradation gelatin matrix with MDA-MB-231 cells and modulation invadopodia formation by RHAMM-target peptides on breast cancer cells. Our results showed that untreated MDA-MB-231 cells degraded almost completely (up to 75 %) total cell area, however, the non-cancer cells ( These results indicate that RHAMM-target peptides can be considered as ant-metastatic agents for prevention of metastasis in breast cancer.
